Show simple item record

dc.contributor.authorFernández de Ullivarri, Miguel
dc.contributor.authorArbulu, Sara
dc.contributor.authorGarcia-Gutierrez, Enriqueta
dc.contributor.authorCotter, Paul D.
dc.date.accessioned2020-07-17T14:33:10Z
dc.date.available2020-07-17T14:33:10Z
dc.date.issued2020-03-17
dc.identifier.citationFernández de Ullivarri M, Arbulu S, Garcia-Gutierrez E and Cotter PD (2020) Antifungal Peptides as Therapeutic Agents. Front. Cell. Infect. Microbiol. 10:105. https://doi.org/10.3389/fcimb.2020.00105en_US
dc.identifier.issn2235-2988
dc.identifier.urihttp://hdl.handle.net/11019/2175
dc.descriptionpeer-revieweden_US
dc.description.abstractFungi have been used since ancient times in food and beverage-making processes and, more recently, have been harnessed for the production of antibiotics and in processes of relevance to the bioeconomy. Moreover, they are starting to gain attention as a key component of the human microbiome. However, fungi are also responsible for human infections. The incidence of community-acquired and nosocomial fungal infections has increased considerably in recent decades. Antibiotic resistance development, the increasing number of immunodeficiency- and/or immunosuppression-related diseases and limited therapeutic options available are triggering the search for novel alternatives. These new antifungals should be less toxic for the host, with targeted or broader antimicrobial spectra (for diseases of known and unknown etiology, respectively) and modes of actions that limit the potential for the emergence of resistance among pathogenic fungi. Given these criteria, antimicrobial peptides with antifungal properties, i.e., antifungal peptides (AFPs), have emerged as powerful candidates due to their efficacy and high selectivity. In this review, we provide an overview of the bioactivity and classification of AFPs (natural and synthetic) as well as their mode of action and advantages over current antifungal drugs. Additionally, natural, heterologous and synthetic production of AFPs with a view to greater levels of exploitation is discussed. Finally, we evaluate the current and potential applications of these peptides, along with the future challenges relating to antifungal treatments.en_US
dc.language.isoenen_US
dc.publisherFrontiers Media SAen_US
dc.relation.ispartofseriesFrontiers in Cellular and Molecular Biology;10
dc.rightsAttribution-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-sa/3.0/us/*
dc.subjectantifungal peptidesen_US
dc.subjectantimicrobial peptidesen_US
dc.subjectmycosesen_US
dc.subjectantimicrobial resistanceen_US
dc.subjectproductionen_US
dc.subjectnew therapiesen_US
dc.titleAntifungal Peptides as Therapeutic Agentsen_US
dc.typeArticleen_US
dc.embargo.terms2021-03-21en_US
dc.identifier.doihttps://doi.org/10.3389/fcimb.2020.00105
dc.contributor.sponsorScience Foundation Irelanden_US
dc.contributor.sponsorEuropean Unionen_US
dc.contributor.sponsorTeagasc Walsh Fellowship Programmeen_US
dc.contributor.sponsorGrantNumberSFI/12/RC/2273en_US
dc.contributor.sponsorGrantNumber754535en_US
dc.contributor.sponsorGrantNumber2015066en_US
dc.source.volume10


Files in this item

Thumbnail
Name:
fcimb-10-00105.pdf
Size:
797.1Kb
Format:
PDF
Description:
main article

This item appears in the following Collection(s)

Show simple item record

Attribution-ShareAlike 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-ShareAlike 3.0 United States